

Structure of human uropepsin at 2.45 Å resolution

Fernanda Canduri,^a Lívia G. V. L. Teodoro,^b Valmir Fadel,^a Carla C. B. Lorenzi,^a Valdemar Hial,^b Roseli A. S. Gomes,^b João Ruggiero Neto^a and Walter F. de Azevedo Jr^{a,c*}

^aDepartamento de Física, IBILCE, UNESP, São José do Rio Preto, SP 15054-000, Brazil,

^bDepartamento de Ciências Biológicas, FMTM, Uberaba, MG 38015-050, Brazil, and ^cCenter for Applied Toxinology, Instituto Butantan, Av. Vital Brasil, 1500 São Paulo, SP 05503-900, Brazil

Correspondence e-mail:
walterfa@df.ibilce.unesp.br

The molecular structure of human uropepsin, an aspartic proteinase from the urine produced in the form of pepsinogen A in the gastric mucosa, has been determined by molecular replacement using human pepsin as the search model. Crystals belong to space group $P2_12_12_1$, with unit-cell parameters $a = 50.99$, $b = 75.56$, $c = 89.90$ Å. Crystallographic refinement led to an R factor of 0.161 at 2.45 Å resolution. The positions of 2437 non-H protein atoms in 326 residues have been determined and the model contains 143 water molecules. The structure is bilobal, consisting of two predominantly β -sheet lobes which, as observed in other aspartic proteinases, are related by a pseudo-twofold axis. A model of the uropepsin–pepstatin complex has been constructed based on the high-resolution crystal structure of pepsin complexed with pepstatin.

Received 10 September 2000
Accepted 23 August 2001

PDB Reference: uropepsin,
1flh.

1. Introduction

Aspartic proteinases (E.C. 3.4.23) form a class of proteolytic enzymes that share the same catalytic apparatus. Members of the aspartic proteinase family can be found in different organisms ranging from humans to plants and retroviruses. The best known sources are in the mammalian stomach, yeast and fungi, with porcine pepsin as the archetype, having been the first enzyme in this family to be sequenced and crystallized (Szecsi, 1992).

Aspartic proteinases are classified as the fourth major class of proteolytic enzymes, distinct from the serine-, cysteine- and metalloproteinases (Hara *et al.*, 1993). The functions of these enzymes are manifold, from non-specific digestion of proteins to highly specialized processing of proteinaceous substrates. The substrate-binding sites of aspartic proteinases, being extended, are capable of interacting with up to seven amino-acid residues of a substrate (Filippova *et al.*, 1996). The aspartic proteinases are characterized by the presence of two aspartic acid residues at the active site. They tend to cleave between hydrophobic amino acids, but secondary interactions are important in the definition of their specificity (Powers *et al.*, 1977). Extensive homology between sequences has been observed among the enzymes belonging to this family.

The catalytic apparatus in all the aspartic proteinases is virtually the same and the differences among these enzymes arise mainly from the differences in specificity resulting from the structural evolution of the sites for substrate side-chain binding. The hypothesis that the aspartic proteinases share the same catalytic apparatus is also supported by the fact that they are universally inhibited by pepstatin, a transition-state analogue inhibitor (Marciniszyn *et al.*, 1976).

The gastric proteinases consist of single polypeptidic chains with three intramolecular disulfide bridges. In the sequences of these enzymes there is a predominance of side-chain carboxyl groups and the presence of a relatively large number of residues of prolines and aromatic amino acids (Plebani, 1993). All the gastric proteinases have a high content of dicarboxylic and β -hydroxy amino acids, but rather low contents of basic amino acids (Foltmann, 1981).

Pepsin is produced by the human gastric mucosa in seven different zymogen isoforms (Foltmann, 1981). These have been subdivided into two types: pepsinogen A (PGA1-5) and pepsinogen C (PGC6 and 7), both consisting of molecular variants (isozymogens) that differ in net ionic charge (Samloff & Taggart, 1987). Pepsinogens are not secreted merely into the gastric lumen but also into the systemic circulation (Ten Kate *et al.*, 1988).

Pepsinogens A and C are translocated from the peptic cells into the circulation and are present in serum (Samloff & Townes, 1970). However, only pepsinogen A can be found in urine by electrophoresis (Samloff & Townes, 1970), indicating a different renal handling of pepsinogen A and pepsinogen C (Ten Kate *et al.*, 1988). Studies comparing the proteolytic activity of serum and urine have shown that the amount of pepsinogens in the urine correlate with the levels in serum. The concentration of pepsinogens in the urine, however, exceeds serum levels by about 10–100 times (Hirschowitz *et al.*, 1957), which indicates a high clearance rate from the blood (Ten Kate *et al.*, 1988). The values of molecular weights of these proteins are around 40 000 Da for the zymogens and about 35 000 Da for the active enzymes.

The zymogens have a relatively higher amount of basic amino acids and, where the sequence is known, these extra basic amino acids are located in the amino-terminal segment of the peptide chain. There is evidence suggesting that this is a general structural feature of zymogens for the gastric proteinases (Foltmann, 1981). At neutral pH, the zymogens are stabilized in an inactive conformation by means of electrostatic interactions between basic amino-acid residues in the N-terminal part of the peptide chain and the negative charges of the dicarboxylic acids in the enzyme moiety of the enzyme. By lowering the pH the carboxyl groups become protonated and the zymogen molecules undergo a conformational change leading to enzymatic activity without cleavage of a peptide bond. At pH 2, this conformational change, in which the active site is uncovered, occurs as a first-order reaction and the change is at least partly reversed by raising the pH (Foltmann, 1981). The reaction proceeds by autocatalytic limited proteolysis, which finally removes 42–47 amino-acid residues from the N-terminal end of the zymogens (Foltmann, 1988).

Various enzymes are known to be secreted into human urine as normal components (Kuser *et al.*, 1999). Changes in the activities of urinary enzymes are observed when our body conditions are physiologically abnormal (Rabb, 1972). The urinary enzymes have not been studied in detail and should be characterized for their origin organs and tissues, and their properties (Minamiura *et al.*, 1984).


PGA and PGC are of medical interest as tumour markers. Low serum PGA levels are found in patients with atrophic gastritis (Samloff *et al.*, 1982) or gastric cancer (Stemmerman *et al.*, 1985). Recent mass screening also revealed that serum PGA levels and the PGA/PGC ratio are potentially useful parameters for the diagnosis of gastric cancer (Hattori *et al.*, 1995).

The properties of uropepsin obtained by activation of uropepsinogen were considered to be similar to those of human gastric pepsin. There is evidence that some amounts of the proenzyme produced in stomach tissue come into the bloodstream and finally into the urine, passing through the membranes of certain renal cells without undergoing any serious modifications (Minamiura *et al.*, 1984).

Tang (1976) incubated uropepsinogen with pepstatin at pH 6.8 and it was not converted to uropepsin even on subsequent incubation at pH 2.0 or upon addition of active pepsin. Also, no intermediate peptides were observed. These results suggest that the conversion of uropepsinogen to uropepsin takes place by autoactivation upon secretion into the urine and not by a bimolecular mechanism (Tang, 1976). On the other hand, it was made clear that the peptide segments liberated by activation of uropepsinogen have an important role in the stabilization of uropepsin, especially in the thermal and pH stabilities, as has been reported by Pearlmann (1963).

Human pepsin consists of up to four isoforms of pepsinogen A with differing enzymatic properties (Tarasova *et al.*, 1994). Uropepsin is one of these, which has the substitution Leu→Val at the position 291.

There are residues contributing to the specificity pockets in the different enzymes. Significant differences in the types of interactions are observed in the S_4 , S_3 , S_2 , S_1 , S'_1 , S'_2 and S'_3 pockets which may be responsible for the differences in specificities. The specificities of proteinases are often characterized by the amino-acid residues adjacent to the peptide bond which is hydrolysed, but substrate binding and specificity may involve amino-acid residues which are located in positions two to four residues away from the peptide bond that is cleaved. In an aspartic proteinase with an extended binding site, the binding subsites (S) and the corresponding positions of amino-acid residues (P) are designated as shown below (Foltmann, 1981).



The substitution of Leu291 by Val291 is likely to affect the specificity at S'_3 and perhaps also at S'_1 (Fujinaga *et al.*, 1995).

This article describes the structure of human uropepsin and its model with the pepstatin inhibitor. The investigation was made in order to gain further insight into the chemistry and functions of this protein.

Table 1

Data-collection statistics for both data sets.

X-ray source	R-AXIS IV	LNLS
Unit-cell parameters		
<i>a</i> (Å)	51.08	50.99
<i>b</i> (Å)	75.91	75.56
<i>c</i> (Å)	89.99	89.90
No. of measurements with $I > 2\sigma(I)$	17686	24189
No. of independent reflections	10232	13134
R_{sym}^{\dagger} (%)	10.4	7.7
Highest resolution shell (Å)	3.5–2.8	2.51–2.45
Completeness in the highest resolution shell (%)	79.3	99.1
R_{sym}^{\dagger} in the highest resolution shell (%)	18.5	30.3

$\dagger R_{\text{sym}} = 100 \sum |I(h) - \langle I(h) \rangle| / I(h)$, where $I(h)$ is the observed intensity and $\langle I(h) \rangle$ is the mean intensity of reflection h over all measurements of $I(h)$.

2. Materials and methods

2.1. Purification of uropepsin

Human uropepsin has been extracted from the urine of healthy young individuals without renal disease. The urine was stored in bottles containing 6.0 M HCl solution. 5 l of this urine was filtered and dialyzed against distilled water. The solution was concentrated to a final volume of 50 ml and lyophilized. Uropepsin was purified using the same procedure as described for human pepsin (Gomes *et al.*, 1996). Briefly, uropepsin purification was performed by a three-step procedure: DEAE bio gel (Biorad) chromatography, Mono Q 5/5 HR column (Pharmacia) chromatography (FPLC) and gel filtration (FPLC) on a Superdex 10/75 column (Pharmacia).

2.2. Catalytic activity

Kinetic parameters were measured by the hydrolysis of a synthetic fluorogenic peptide containing at the extremities the chromophore *O*-aminobenzoyl (Abz) and its quenching partner *N*-(2,4-dinitrophenyl) ethylenediamine (Eddnp), which are separated by eight amino-acid residues including two consecutive phenylalanine residues (Filippova *et al.*, 1996). Cleavage of the peptide between these hydrophobic residues results in the separation of two fragments and the consequent dequenching of the Abz, which leads to an increase in the fluorescence signal. Catalytic activity from pepsin 3A shows the value for K_m is $1.53 \pm 0.11 \mu\text{M}$ and k_{cat} is $5.92 \pm 0.21 \text{ s}^{-1}$. For uropepsin, the value for K_m is $1.76 \pm 0.09 \mu\text{M}$ and k_{cat} is $6.01 \pm 0.11 \text{ s}^{-1}$, using Abz-Lys-Pro-Ile-Glu-Phe-Phe-Arg-Leu-Eddnp as synthetic substrate in 0.2 M acetate buffer pH 5.0. The concentration of the substrate varied in the range 0.117–5.66 μM . k_{cat} values were calculated after titration of the active site with pepstatin.

2.3. Crystallization

Crystals of uropepsin were obtained in several different crystallization conditions using the hanging-drop vapour-diffusion and sparse-matrix methods (Jancarik & Kim, 1991). The best crystals were obtained after one week from drops in which 3 μl of enzyme solution was mixed with an equal volume of 0.1 M HEPES buffer pH 7.0 containing 2% polyethylene glycol 400 and 2.0 M ammonium sulfate. Crystals were

Table 2

Refinement statistics for human uropepsin.

Resolution (Å)	12.0–2.45
R factor † (%)	16.1
$R_{\text{free}}^{\ddagger}$ (%)	25.1
B values § (Å ²)	
Main chain	15.0
Side chains	14.1
Waters	29.5
Observed r.m.s. deviations from ideal geometry	
Bond lengths (Å)	0.009
Bond angles (°)	1.61
Dihedrals (°)	27.04
No. of water molecules	143

$\dagger R = 100|F_{\text{obs}} - R_{\text{calc}}| / \sum F_{\text{obs}}$, the sums being taken over all reflections with $F/\sigma(F) > 2$ cutoff. $\ddagger R_{\text{free}} = R$ for 10% of the data which were not included during crystallographic refinement. \S Average B values for all non-H atoms.

mounted in capillary tubes of borosilicate glass for X-ray data collection (Canduri *et al.*, 1998).

2.4. Data collection

X-ray diffraction data were firstly collected from a single urinary aspartic proteinase crystal at room temperature using an R-AXIS IV imaging-plate system and graphite-monochromated Cu $K\alpha$ X-rays radiation generated by a Rigaku RU-300 rotating-anode generator operated at 50 kV and 100 mA at a crystal-to-detector distance of 150 mm. 40 frames were collected using an oscillation range of 2.5°. The exposure time per frame was 20 min. The X-ray diffraction data were processed to 2.8 Å resolution and scaled using the program *PROCESS* (Higashi, 1990). A second X-ray diffraction data set was collected at a wavelength of 1.38 Å using the Brazilian National Synchrotron Laboratory (Station PCr, Laboratório Nacional de Luz Síncrotron, LNLS, Campinas, Brazil; Polikarpov, Oliva *et al.*, 1998; Polikarpov, Oliva *et al.*, 1998) and a 34.5 cm MAR imaging-plate detector (MAR Research) with an exposure time of 3 min per image at a crystal-to-detector distance of 175 mm. Using an oscillation range of 1.5°, 65 images were collected and the raw X-ray diffraction data were processed to 2.45 Å resolution using the program *DENZO* (Gewirth, 1995) and scaled with the program *SCALEPACK* (Gewirth, 1995). Autoindexing procedures combined with analysis of the X-ray diffraction pattern and averaging of equivalent intensities were used in characterization of the Laue symmetry (Canduri *et al.*, 1998).

The crystal belongs to the orthorhombic space group $P2_12_12_1$ and the volume of the unit cell is $346 \times 10^3 \text{ \AA}^3$, compatible with one monomer in the asymmetric unit with a V_M value of $2.17 \text{ \AA}^3 \text{ Da}^{-1}$. Assuming a value of $0.74 \text{ cm}^3 \text{ g}^{-1}$ for the protein partial specific volume, the calculated solvent content in the crystal is 43.3% and the calculated crystal density is 1.21 g cm^{-3} . The X-ray diffraction data statistics are summarized in Table 1.

2.5. Crystal structure

The crystal structure of human uropepsin was determined by standard molecular-replacement methods with the programs *AMoRe* (Navaza, 1994) and *X-PLOR* (Brünger,


Table 3

Eulerian angles and fractional coordinates after translation-function computation.

Protein	α ($^{\circ}$)	β ($^{\circ}$)	γ ($^{\circ}$)	x	y	z	CC (%)	R^{\dagger} (%)
1eag	33.83	65.23	76.65	0.2231	0.1861	0.2065	14.4	54.1
1lya	156.00	46.61	121.10	0.3169	0.4727	0.0587	39.4	46.7
1zap	122.98	39.94	38.05	0.2905	0.2007	0.3434	14.4	55.2
1bbs	152.67	50.03	121.40	0.3250	0.4819	0.0588	26.5	50.8
1mpp	21.80	90.00	4.34	0.2000	0.1747	0.0514	16.2	53.5
2ren	30.54	40.01	235.18	0.3283	0.0154	0.4332	33.1	48.4
4apr	149.04	44.86	125.18	0.3176	0.4861	0.0618	22.1	52.5
1psn	24.44	46.13	59.44	0.3224	0.0247	0.4385	67.8	35.0
3app	146.53	46.99	307.78	0.3058	0.4739	0.0524	20.2	53.2
1cms	152.27	45.15	122.87	0.3209	0.4742	0.0610	39.3	48.9

$\dagger R_{\text{factor}} = 100 \sum |F_{\text{obs}} - F_{\text{calc}}| / \sum F_{\text{obs}}$, the sums being taken over all reflections with $F/\sigma(F) > 2$ cutoff.

1992), using as search model the structure of human pepsin (Fujinaga *et al.*, 1995). Structure refinement was performed using *X-PLOR* (Brünger, 1992). The atomic positions obtained from molecular replacement were used to initiate the crystallographic refinement with an overall B factor of 20 \AA^2 .

**Figure 1**

Omit map ($F_{\text{obs}} - F_{\text{calc}}$, 2σ cutoff) for the region where there is a substitution (isoform Leu \rightarrow Val) in the position 291.

Table 4

Fractional coordinates after translation-function computation for other possible space groups.

Space group	T_x	T_y	T_z	CC (%)	R^{\dagger} (%)
$P2_12_12$	0.0748	0.1244	0.1889	38.0	46.4
$P222_1$	0.0702	0.0254	0.3940	38.5	46.5
$P222$	0.0080	0.0045	0.0104	26.4	51.1

$\dagger R_{\text{factor}} = 100 \sum |F_{\text{obs}} - F_{\text{calc}}| / \sum F_{\text{obs}}$, the sums being taken over all reflections with $F/\sigma(F) > 2$ cutoff.

Several attempts at cocrystallizing uropepsin with pepstatin did not produce crystals of high quality. A model of the uropepsin–pepstatin complex has been constructed. The model was based on the high-resolution crystal structure of pepsin complexed with pepstatin. The protein modelling was performed by superposition of the three domains of the pepsin part of the pepsin–pepstatin complex (PDB code 1psn; Fujinaga *et al.*, 1995) onto the uropepsin structure using the program *ProFit* V. 1.8 (Martin, 1992–1998). The coordinates of the pepstatin were obtained using HIC-Up (<http://xray.bmc.uu.se/hicup/>). The pepstatin model was moved as a rigid body to approximately the same relative orientation as the pepstatin in the binary complex (1psn) without any modification of the side-chain positions of the pepstatin. The coordinates of the complex were minimized using the program *X-PLOR* (Brünger, 1992) through 200 cycles of positional refinement with the weight of the X-ray term of energy function set to zero. During the 200 cycles of positional refinement the energy decreases from 12×10^6 to $13\,250 \text{ kJ mol}^{-1}$. This model was used for comparisons with the binary complex pepsin–pepstatin.

Root-mean-square deviation (r.m.s.d.) differences from ideal geometries for bond lengths, angles and dihedrals were calculated with *X-PLOR* 3.1 (Brünger, 1992) and are presented in Table 2. The overall stereochemical quality of the final model for uropepsin was assessed with *PROCHECK* (Laskowski *et al.*, 1993). Atomic models were superposed using the program *LSQKAB* from *CCP4* (Collaborative Computational Project, Number 4, 1994).

3. Results and discussion

3.1. Molecular replacement and refinement

Peak analysis of the self-rotation function did not reveal the presence of any significant local symmetry axis, suggesting that a single subunit is contained in the asymmetric unit. This was in agreement with the estimated values of the crystal solvent content and V_M value (Matthews, 1968).

The results of molecular replacement using ten different search models are listed in Table 3. The correlation coefficients after translation function computation range from 14.4 to 67.8% and the R

Table 5

Hydrogen-bonding contacts between human uropepsin and its 14 symmetry-related neighbours.

Group in <i>x, y, z</i>	Symmetry-related group			Symmetry element†	Hydrogen-bond distance (Å)
Glu69	OE1	Cys249	O	ii	3.68
Glu69	OE1	Ser250	O	ii	3.14
Glu69	OE1	Ser253	OG	ii	2.73
Tyr86	OH	Ser248	OG	ii	3.41
Ser131	O	Ser250	OG	ii	3.92
Asn142	O	Ser241	OG	ii	3.74
Glu3	O	Thr51	O	iv	3.40
Thr17	OG1	Ser46	O	iv	2.82
Ala24	O	Ser110	OG	iv	3.21
Gln90	OE1	Tyr113	OH	iv	2.63
Tyr175	O	Glu202	OE2	iv	3.83
Ser178	OG	Asp234	O	iv	3.41
Asn180	OD1	Ser233	O	iv	3.28
Ser226	OG	Asp257	OD2	iv	2.66

† Symmetry operators: (i) *x, y, z*, (ii) $-x + \frac{1}{2}, -y, z + \frac{1}{2}$, (iii) $-x, y + \frac{1}{2}, -z + \frac{1}{2}$, (iv) $x + \frac{1}{2}, -y + \frac{1}{2}, -z$.

factors range from 35.0 to 54.1%. The highest peak calculated for the translation function using *AMoRe* (Navaza, 1994) was 42.8% above the next highest peak. The search model which presented the best correlation coefficient and *R* factor was pepsin 3A from *Homo sapiens* (PDB code 1psn). This search model was also submitted to molecular replacement using the program *X-PLOR* and the solution obtained after the translation search was $\alpha = 23.6$, $\beta = 47.0$, $\gamma = 59.8^\circ$, $x = 0.314$, $y = 0.029$, $z = 0.443$, $R = 34.6\%$, close to that obtained by *AMoRe* (Navaza, 1994).

Translation functions for space groups *P222*, *P222₁* and *P2₁2₁2₁* have been computed using the coordinates of pepsin 3A as the search model and the results are listed in Table 4. The correlation coefficients after translation-function computation for the three space groups range from 26.4 to 38.0% and the *R* factors range from 46.4 to 51.1%, which strongly indicates that the correct space group is *P2₁2₁2₁*.

Uropepsin has only one amino-acid difference compared with the human gastric pepsin sequence used in the molecular replacement. A close examination of the electron-density




Figure 2

Plot showing *R* and *R_{free}* values along with all steps in the refinement of uropepsin. (I) Rigid-body refinement, (II) positional refinement, (III) simulated annealing, (IV) positional refinement, (V) *B*-factor refinement, (VI) *B*-factor refinement with 143 molecules of water.

Table 6

Hydrogen-bonding contacts between human pepsin and its 22 symmetry-related neighbours.

Group in <i>x, y, z</i>	Symmetry-related group			Symmetry element †	Hydrogen-bond distance (Å)
Glu3	OE1	Ser254	OG	iv	3.80
Glu3	OE2	Ser250	O	iv	3.80
Gly144	O	Gln266	OE1	iv	3.60
Val146	O	Gln266	OE1	iv	3.69
Ser147	OG	Thr261	OG1	iv	2.90
Ser147	O	Thr198	OG1	iv	3.70
Asp171	OD1	Glu208	OE1	iv	3.73
Glu279	OE1	Glu294	OE2	i	3.26
Glu279	OE2	Glu294	OE2	i	3.95
Ser46	O	Glu69	OE1	ii	3.68
Ser46	O	Thr70	OG1	ii	2.23
Ser47	OG	Glu69	OE2	ii	2.90
Glu3	OE1	Ser250	O	iv	3.26
Asp171	OD1	Ser248	OG	iv	3.41
Asp171	OD2	Ser248	OG	iv	2.35
Ser172	OG	Glu208	OE1	iv	3.73
Ser172	OG	Glu208	OE2	iv	2.56
Glu202	OE1	Asp314	OD1	iv	3.20
Glu202	OE1	Asp314	OD2	iv	3.35
Glu202	OE1	Asn317	OD1	iv	3.27
Glu202	OE2	Asp314	OD2	iv	3.30
Glu202	OE2	Asn317	OD1	iv	3.42

† Symmetry operators: (i) *x, y, z*, (ii) $-x + \frac{1}{2}, -y, z + \frac{1}{2}$, (iii) $-x, y + \frac{1}{2}, -z + \frac{1}{2}$, (iv) $x + \frac{1}{2}, -y + \frac{1}{2}, -z$.

maps identified the isoform in the present study to be isoform Leu291→Val291. A omit map for this region is shown in Fig. 1. The substitution of Leu291 by Val291 was performed and the modified model was submitted to crystallographic refinement using slow-cooling protocols as implemented in the program *X-PLOR* (Brünger, 1992). The evolution of the values of *R* and *R_{free}* over six stages of the refinement is shown in Fig. 2. At the end of the refinement, after adding water molecules and analyzing the temperature factors [values above 60 Å were removed from the model and new analysis of the (*F_{obs}* - *F_{calc}*) map was carried out], the *R* factor was 16.1% and *R_{free}* was 25.1%, with 143 molecules of water in the final model. The human uropepsin consists of 2437 non-H protein atoms. The overall quality of the of electron-density map can be seen in Fig. 3. The active site is shown with the two aspartate residues (Asp32 and Asp215). The atomic coordinates and the structure factors have been deposited in the Protein Data Bank.

3.2. Quality of the models

Fig. 4 shows the Ramachandran diagram ϕ - ψ plot. The overall rating for the model is 'good'. In native uropepsin, 84.2% of the residues are found to occur in the most favoured regions (A, B, L) of the plot. Two residues (Asp11 and Asp158) fall in the generously allowed regions of the map (Fig. 4), but analysis of the electron-density map ($2F_{obs} - F_{calc}$) agrees with their positioning. There are 34 glycine residues and 17 proline residues in the protein.

3.3. Overall description

The refined model of uropepsin is bilobal, consisting of two predominantly β -sheet lobes which, as observed in other

aspartic proteinases, are related by a pseudo-twofold axis. The structure of human uropepsin follows closely the structure of porcine pepsin described previously (Cooper *et al.*, 1990). The uropepsin structure can be divided in three domains analogous to the three domains of porcine pepsin (Sielecki *et al.*, 1990). The central domain consists of a six-stranded anti-

parallel β -sheet that serves as a backbone to the active-site region of the molecule. It is made up of residues Val1–Leu6, Asp149–Val184 and Glu308–Ala326. The N-terminal lobe is composed of residues Glu7–Gln148 and the C-terminal lobe is made up of residues Thr185–Arg307. The lobes consist of orthogonally packed β -sheets with the N- and C-terminal lobes having three and two layers, respectively. The overall structure and its division into three domains can be appreciated in Fig. 5.

Fig. 6 shows the r.m.s.d. plot of the superposition of the uropepsin with the pepsin 3A. It is important to remember that the primary sequence of uropepsin is the same as that of pepsin 3A, except for residue 291 (Leu \rightarrow Val). We accomplished three superpositions (i) using all protein atoms (except for the atoms of residue 291), (ii) using the main-chain atoms (C, C $^{\alpha}$, N, O) and (iii) the C $^{\alpha}$ atoms. The overall r.m.s.d. for the first superposition was 0.737 Å; for the main chain it was 0.528 Å and for the C $^{\alpha}$ atoms it was 0.529 Å.

Two residues showed r.m.s.d.s larger than 2.5 Å, as can be seen in Fig. 6(c). One of them was Asp158 (r.m.s.d. of 2.64 Å). This residue is in the region generously allowed in the Ramachandran plot for the uropepsin structure; nevertheless, it is inside the electron-density map. The other residue was Glu294 (r.m.s.d. of 2.91 Å). The reason for this value is that Glu294 is exposed to solvent, possessing great flexibility in both structures.

3.4. Accuracy of coordinates

Ignoring low-resolution data, a Luzzati plot (Luzzati, 1952) gives the best correlation between the observed and calculated data for a predicted mean coordinate error of 0.19 Å.

3.5. Thermal vibration parameters

Fig. 7 illustrates the wide variation in residue-averaged B factors for both main-chain and side-chain atoms in the final model. The average B factor for main-chain atoms is 15.0 Å², whereas that for side-chain atoms is 14.1 Å². B factors for water molecules range from 12.24 to 46.81 Å², with an average of 29.5 Å² (Table 2).

Although the pepsin structure has been solved at a resolution higher than that of uropepsin, several regions of the pepsin structure have high B factors, indicating disorder. The same regions in the uropepsin




Figure 3

Electron-density map ($2F_{\text{obs}} - F_{\text{calc}}$, 1σ cutoff) of the active site of the human uropepsin showing aspartic acid residues 32 and 215.

structure present much lower B factors. This is probably because of the lower solvent content of the uropepsin crystals.




Figure 4 Ramachandran plot for the uropepsin. The regions A, B and L are most favoured, the regions a, b, l and p are allowed and ~a, ~b, ~l and ~p are the generously allowed regions. Glycine residues are shown as triangles.




Figure 5 Ribbon diagram of the human uropepsin generated by *Molscript* (Kraulis, 1991; Merritt & Murphy, 1994) and *Raster3D* (Merritt & Murphy, 1994). The three domains of uropepsin can be observed: the C-terminal domain is in green, the central domain is in red and the N-terminal domain is in cyan.

3.6. Crystal contacts and packing

Intermolecular contacts in the uropepsin crystal have been analyzed. Although many water-mediated intermolecular hydrogen-bonding contacts exist, only salt bridges or hydrogen bonds formed directly between the uropepsin molecules are listed in Table 5. An equivalent table has been constructed for pepsin 3A (Table 6). Particularly interesting is the fact that both enzymes were crystallized in the same space group, $P2_12_12_1$, although with different unit-cell parameters. The unit-cell parameters for pepsin are $a = 71.97$, $b = 151.59$, $c = 41.15$ Å, with the unit-cell volume 449×10^3 Å³ and a V_M value of 3.24 Å³ Da⁻¹. The solvent content is 60.5% and the calculated crystal density is 1.13 g cm⁻³.




Figure 6 Plot showing r.m.s.d. between the uropepsin and the human pepsin 3A. (a) Main chain, (b) C^α , (c) all protein atoms.




Figure 7 B factors, full residue (red line) and side chain (black line), for the 326 residues of the uropepsin sequence. Thin lines in black show the average B factor (15.0 and 14.1 Å², respectively).

Table 7
R.m.s.d. values for structural superposition of uropepsin with other aspartic proteinases.

Uropepsin	Human pepsin (1psn)	Human pepsin (1pso)	Human renin (1rne)	Human cathepsin D (1lyb)	Porcine pepsin (4pep)
R.m.s.d. (Å)	0.53	0.63	1.54	1.57	0.55
Number of C $^{\alpha}$ atoms superposed	326	326	292	304	326




Figure 8
Crystal packing for the structures of (a) human uropepsin and (b) human pepsin.

Fig. 8 shows the crystal packing for the structures of the human uropepsin and pepsin. There are four molecules in the unit cell in both structures and the packing is closer with less solvent in uropepsin ($V_{\text{solv}} = 43.3\%$) compared with pepsin.

The uropepsin structure has a total of ten intermolecular contacts compared with 28 observed in human pepsin (PDB code 1psn; Fujinaga *et al.*, 1995). The intermolecular contacts were calculated using *DISTANG* (Collaborative Computational Project, Number 4, 1994). The cutoff for intermolecular contacts ranges from 2.5 to 3.7 Å, depending on the atom type and using standard van der Waals radii. The residues involved in the contacts are different in both proteins. The main residues involved in intermolecular contacts are Glu69, Gln90, Tyr113, Ser226, Ser253 and Asp257 for uropepsin, and Glu3, Ser46, Leu48, Ser68, Thr70, Asp171, Ser248 and Ser250 for pepsin. This difference is a consequence of a different relative orientation in the molecular packing observed between the two crystal structures.

3.7. Comparison with other human enzymes

The amino-acid sequence of human uropepsin is compared with those of the other human aspartic proteinases as well as with that of porcine pepsin in Fig. 9. The sequence identities between uropepsin and other aspartic proteinases are 86.5% for porcine pepsin, 52% for human cathepsin E, 54% for human renin, 48% human cathepsin D and 34% for human gastricsin. Table 7 shows the r.m.s.d. of the equivalent C $^{\alpha}$ atoms after superposition with the program *PROFIT* (McLachlan, 1982). The largest r.m.s.d.s are observed between uropepsin and human cathepsin D, and between uropepsin and renin. The structural similarity correlates with the similarity in the sequences.

3.8. Interactions with pepstatin and substrate-binding sites

A total of 14 hydrogen bonds were observed between uropepsin and pepstatin, most of them involving the catalytic aspartates (Asp32 and Asp215). The hydrogen-bonding pattern between the inhibitor and the enzyme is well conserved in other structurally determined complexes with pepstatin (Suguna *et al.*, 1992; Bailey *et al.*, 1993; Baldwin *et al.*, 1993). The hydrogen-bonding distances between Asp32 and Asp215 in uropepsin and Sta404 (statine) in pepstatin are compatible with the pepsin complex; however, the hydrogen-bonding distances between Thr77–Val403 and Gly217–Sta404 of uropepsin and inhibitor are greater than those observed for the complex of pepsin and pepstatin (Fig. 10; Table 8). As observed for crystallographic structures of complexes of inhibitors bound to aspartic proteinases, pepstatin in the modelled complex adopts an extended conformation, with the first statyl hydroxyl O atom occupying a




Figure 9
Sequence alignment of human aspartic proteinases and porcine pepsin. The multiple alignment was performed with the program *CLUSTALW* (Higgins *et al.*, 1992). UROP_HUM, human uropepsin (Fujinaga *et al.*, 1995); PEPs_PIG, porcine pepsin (Tang *et al.*, 1973); GAST_HUM, human gastricsin (Hayano *et al.*, 1988); CATE_HUM, human cathepsin E (Azuma *et al.*, 1989); CATD_HUM, human cathepsin D (Faust *et al.*, 1985); RENI_HUM, human renin (Imai *et al.*, 1983). Sequence numbering based on the pepsin sequence.




Figure 10
Representation of the potential hydrogen-bonding interactions (dashed) between aspartic proteinase (pepsin) and pepstatin (Fujinaga *et al.*, 1995).

position in the active site between the carboxyl groups of Asp32 and Asp215. The specificity and affinity between enzyme and its inhibitor depend on directional hydrogen bonds and ionic interactions, as well as on the shape complementarity of the contact surfaces of both partners (de Azevedo *et al.*, 1996, 1997; Kim *et al.*, 1996).

The electrostatic potential surface of native uropepsin and the model complex with pepstatin were calculated with *GRASP* (Nicholls *et al.*, 1991). The same was performed with

native and inhibited pepsin 3A. The two molecular surfaces were compared considering coordinates of the native and inhibited proteins. There is a conformational change in the structure when the inhibitor binds in the active site. The change is relatively small, with an r.m.s.d. difference in the coordinates of all the C α atoms of 0.33 Å after superposition for pepsin 3A and 0.44 Å for uropepsin. It can be clearly seen as a relative movement of the domains to enclose the inhibitor more closely in both binary complexes (Fig. 11).

We could observe that the overall structures of uropepsin and pepsin 3A are mostly negatively charged. The structures have few histidine (1), lysine (0) and arginine (3) residues. The active sites are strongly negative, as shown in Fig. 11.

The binding sites from S₄ to S₃' are defined by the interactions of the residues P₄ to P₃' of the inhibitor with the enzyme. It is unlikely that there are additional binding sites beyond these sites. The main-chain N atom of the P₃' residue forms a hydrogen bond to Thr74. The S₄ pocket is flat and very accessible to solvent. The pockets S₁ and S₃ are contiguous, with the carbonyl O atom of Gly217 providing some separation of the two pockets. The S₁ pocket tends to be hydrophobic in nature, whereas the S₃ pocket is mainly polar. The S₂ and S₁' pockets are mainly hydrophobic. The S₂' pocket is clearly

defined by the P_2' alanine residue. The main chain of the inhibitor makes a hydrogen bond to the Gly34 O atom and accepts a hydrogen bond from Tyr189 OH of the S_2' pocket (Table 9) (Fujinaga *et al.*, 2000).




Figure 11
Electrostatic potential surface of the pepsin (a) without inhibitor and (b) with inhibitor and of the uropepsin (c) without inhibitor and (d) with inhibitor, calculated with *GRASP* (Nicholls *et al.*, 1991) and shown from -50 kT (red) to $+50$ kT (blue). Uncharged regions are in white.




Figure 12
Superimposed binding pockets of the uropepsin-pepstatin complex (thick line) and the pepsin-pepstatin complex (thin line).

Table 8
Intermolecular hydrogen bonds of pepsin and uropepsin.

Some of the distances are in italics, indicating that there are not hydrogen bonds in these positions in uropepsin; these are present for comparison.

Hydrogen bonds between active site and inhibitor		Distance (Å)	
Pepstatin	Enzyme	Uropepsin	Pepsin
Sta404 OH	Asp215 O ^{δ2}	2.69	2.69
	Asp215 O ^{δ1}	2.71	2.96
	Asp32 O ^{δ2}	3.10	3.36
	Asp32 O ^{δ1}	2.71	2.68
Sta404 N	Gly217 O	3.49	2.95
Sta404 OH	Gly217 O	<i>4.05</i>	3.52
Ala405 N	Gly34 O	3.21	2.91
Ala405 O	Tyr189 O ^γ	3.24	2.66
Val402 N	Ser219 O ^γ	2.76	2.98
Val402 O	Ser219 N	2.75	2.99
Val403 N	Thr77 O ^γ	5.33	3.08
Val403 O	Thr77 N	<i>4.12</i>	2.95
	Gly76 N	3.54	2.99
Sta404 O	Gly76 N	3.15	2.92
Sta406 N	Thr74 O	3.14	2.96

The only difference observed between pepsin 3A and uropepsin is the substitution Leu→Val at position 291, located in S_3' pocket. Nevertheless, it seems that this substitution in the binding pocket does not affect the k_{cat} values: the values of k_{cat} determined for uropepsin and pepsin using the same substrate are 6.01 ± 0.11 and 5.92 ± 0.21 s⁻¹, respectively. Furthermore, the substitution Leu→Val keeps the hydrophobicity in the S_3' pocket and the position adopted by the valine side chain does not affect the substrate binding.

The hydrogen bonds between Thr77–Val403 and Gly217–Sta404 observed in the pepsin-pepstatin complex are not observed in the uropepsin-pepstatin complex (Table 8). However, a close examination of the binary complexes pepsin-pepstatin and the model of uropepsin-pepstatin shows clearly that the inhibitor adopts the same orientation in both complexes (Fig. 12). Furthermore, the hydrogen bonds between Asp32 and Asp215 and the inhibitor are conserved in both complexes. This structural similarity confirms the same activity against pepstatin observed in the two enzymes.

We thank Mr J. R. Brandão Neto and Dr I. Polikarpov (LNLS) for their help in the synchrotron data collection. We also thank Andressa Salb  dos Santos Oliveira for revision of the English. This work was supported by grants from FAPESP, CNPq, CAPES and Fundo Bunka de Pesquisa (Banco Sumitomo).

References

- Azevedo, W. F. Jr de, Leclerc, S., Meijer, L., Havlicek, L., Strnad, M. & Kim, S.-H. (1997). *Eur. J. Biochem.* **243**, 518–526.
 Azevedo, W. F. Jr de, Mueller-Dieckmann, H.-J., Schulze-Gahmen, U., Worland, P. J., Sausville, E. & Kim, S.-H. (1996). *Proc. Natl Acad. Sci. USA*, **93**, 2735–2740.

- Azuma, T., Pals, G., Mohandas, T. K., Couvreur, J. M. & Taggart, R. T. (1989). *J. Biol. Chem.* **264**, 16748–16753.
- Bailey, D., Cooper, J. B., Veerapandian, B., Blundell, T. L., Atrash, B., Jones, D. M. & Szelke, M. (1993). *Biochem. J.* **289**, 363–371.
- Baldwin, E. T., Bhat, T. N., Gulnik, S., Hosur, M. V., Sowder, R. C. II, Cachau, R. E., Collins, J., Silva, A. M. & Erickson, J. W. (1993). *Proc. Natl Acad. Sci. USA*, **90**, 6796–6800.
- Brünger, A. T. (1992). *X-PLOR Version 3.1: A System for Crystallography and NMR*. Yale University Press, New Haven, CT, USA.
- Canduri, F., Teodoro, L. G. V. L., Lorenzi, C. C. B., Gomes, R. A. S., Fontes, M. R. M., Arni, R. K. & de Azevedo W. F. Jr (1998). *Biochem. Mol. Biol. Int.* **46**, 355–363.
- Collaborative Computational Project, Number 4 (1994). *Acta Cryst. D50*, 760–763.
- Cooper, J. B., Khan, G., Taylor, G., Tickle, I. J. & Blundell, T. L. (1990). *J. Mol. Biol.* **214**, 199–222.
- Faust, P. L., Kornfeld, S. & Chirgwin, J. M. (1985). *Proc. Natl Acad. Sci. USA*, **82**, 4910–4914.
- Filippova, I. Yu., Lysogorskaya, E. N., Anisimova, V. V., Suvorov, L. I., Oksenoit, E. S. & Stepanov, V. M. (1996). *Anal. Biochem.* **234**, 113–118.
- Foltmann, B. (1981). *Essays Biochem.* **17**, 52–84.
- Foltmann, B. (1988). *FEBS Lett.* **241**, 69–72.
- Fujinaga, M., Chernaia, M. M., Tarasova, N. I., Mosimann, S. C. & James, M. N. G. (1995). *Protein Sci.* **4**, 960–972.
- Fujinaga, M., Cherney, M. M., Tarasova, N. I., Bartlett, P. A., Hanson, J. E. & James, M. N. G. (2000). *Acta Cryst. D56*, 272–279.
- Gewirth, D. (1995). *The HKL Manual*. Yale University, New Haven, Connecticut, USA.
- Gomes, R. A. S., Chagas, J. R., Juliano, L. & Hial, V. (1996). *Immunopharmacology*, **32**, 76–79.
- Hara, K., Fukuyama, K., Sakai, H., Yamamoto, K. & Epstein, W. L. (1993). *J. Invest. Dermatol.* **100**, 394–399.
- Hattori, Y., Tashiro, H., Kawamoto, T. & Kodama, Y. (1995). *Jpn J. Cancer Res.* **86**, 1210–1215.
- Hayano, T., Sogawa, K., Ichihara, Y., Fujii-Kuriyama, Y. & Takahashi, K. (1988). *J. Biol. Chem.* **263**, 1382–1385.
- Higashi, T. (1990). *J. Appl. Cryst.* **23**, 253–257.
- Higgins, D. G., Bleasby, A. J. & Fuchs, R. (1992). *Comput. Appl. Biosci.* **8**, 189–191.
- Hirschowitz, B. I., Streeten, D. H. P., London, J. A. & Pollard, H. M. (1957). *J. Clin. Invest.* **36**, 1171–1182.
- Imai, T., Miyazaki, H., Hirose, S., Hori, H., Hayashi, T., Kageyama, R., Ohkubo, H., Nakanishi, S. & Murakami, K. (1983). *Proc. Natl Acad. Sci. USA*, **80**, 7405–7409.
- Jancarik, J. & Kim, S.-H. (1991). *J. Appl. Cryst.* **24**, 409–411.
- Kim, S.-H., Schulze-Gahmen, U., Brandsen, J. & de Azevedo, W. F. Jr (1996). *Progress in Cell Cycle Research*, Vol. 2, edited by L. Meijer, S. Guidet & L. Vogel, pp. 137–145. New York: Plenum Press.
- Kraulis, P. J. (1991). *J. Appl. Cryst.* **24**, 946–950.
- Kuser, P., Krauchenco, S., Fangel, A. & Polikarpov, I. (1999). *Acta Cryst. D55*, 1340–1341.
- Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. (1993). *J. Appl. Cryst.* **26**, 283.
- Luzzati, V. (1952). *Acta Cryst.* **5**, 802–810.
- McLachlan, A. D. (1982). *Acta Cryst. A38*, 871–873.
- Marciniszyn, J. Jr, Hartsuck, J. A. & Tang, J. (1976). *J. Biol. Chem.* **251**, 7088–7094.
- Martin, A. C. R. (1992–1998). *ProFit v.1.8*. SciTech Software, Chico, California, USA.
- Matthews, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.
- Merritt, E. A. & Murphy, M. E. P. (1994). *Acta Cryst. D50*, 869–873.
- Minamiura, N., Ito, K., Kobayashi, M., Kobayashi, O. & Yamamoto, T. (1984). *J. Biochem.* **96**, 1061–1069.
- Navaza, J. (1994). *Acta Cryst. A50*, 157–163.
- Nicholls, A., Sharp, K. & Honig, B. (1991). *Proteins Struct. Funct. Genet.* **11**, 281.
- Pearlmann, G. E. (1963). *J. Mol. Biol.* **6**, 452–464.
- Plebani, M. (1993). *Crit. Rev. Clin. Lab. Sci.* **30**, 273–328.
- Polikarpov, I., Oliva, G., Castellano, E. E., Garratt, R., Arruda, P., Leite, A. & Craievich, A. (1998). *Nucl. Instrum. Methods A*, **405**, 159–164.
- Polikarpov, I., Perles, L. A., de Oliveira, R. T., Oliva, G., Castellano, E. E., Garratt, R. & Craievich, A. (1998). *J. Synchrotron Rad.* **5**, 72–76.
- Powers, J. C., Harley, A. D. & Myers, D. V. (1977). *Acid Proteinases, Structure, Function and Biology*, edited by J. Tang, pp. 141–157. New York: Plenum Press.
- Rabb, W. P. (1972). *Clin. Chem.* **18**, 5–25.
- Samloff, I. M. & Taggart, R. T. (1987). *Clin. Invest. Med.* **10**, 215–221.
- Samloff, I. M. & Townes, P. L. (1970). *Gastroenterology*, **58**, 462–469.
- Samloff, I. M., Varis, K., Ihmaki, T., Siurala, M. & Rotter, J. I. (1982). *Gastroenterology*, **83**, 204–209.
- Sielecki, A. R., Fedorov, A. A., Boodhoo, A., Andreeva, N. S. & James, M. N. G. (1990). *J. Mol. Biol.* **214**, 143–170.
- Stemmerman, G. N., Heilbrun, L. K., Nomura, A. & Samloff, I. M. (1985). *Prog. Clin. Biol. Res.* **173**, 213–220.
- Suguna, K., Padlan, E. A., Bott, R., Boger, J., Parris, K. D. & Davies, D. R. (1992). *Proteins Struct. Funct. Genet.* **13**, 195–205.
- Szecs, P. B. (1992). *Scand. J. Clin. Lab. Invest.* **52**(Suppl. 210), 5–22.
- Tang, J. (1976). *Trends Biochem. Sci.* **1**, 205–208.
- Tang, J., Sepulveda, P., Marciniszyn, J. J., Chen, K. C., Huang, W. Y., Tao, N., Liu, D. & Lanier, J. P. (1973). *Proc. Natl Acad. Sci. USA*, **70**, 3437–3439.
- Tarasova, N., Denslow, N. D., Parten, B. F., Tran, N., Nhuyen, H. P., Jones, A., Roberts, N. B. & Dunn, B. M. (1994). In *Aspartic Proteinases and their Inhibitors*, edited by K. Takahashi. New York: Plenum Press.
- Ten Kate, R. W., Pals, G., Pronk, J. C., Bank, R. A., Eriksson, A. W., Donker, A. B. J. M. & Meuwissen, S. G. M. (1988). *Clin. Sci.* **75**, 649–654.